ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis
BackgroundHepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Increasing evidence revealed that long noncoding RNAs (lncRNAs) were frequently involved in various malignancies. Here, we explored the clinical significances, roles, and mechanisms of lncRNA ADORA2A antisense RNA 1...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.754835/full |
| _version_ | 1818890989507444736 |
|---|---|
| author | Jian Pu Ya Zhang Anmin Wang Zebang Qin Chenyi Zhuo Wenchuan Li Zuoming Xu Qianli Tang Jianchu Wang Huamei Wei |
| author_facet | Jian Pu Ya Zhang Anmin Wang Zebang Qin Chenyi Zhuo Wenchuan Li Zuoming Xu Qianli Tang Jianchu Wang Huamei Wei |
| author_sort | Jian Pu |
| collection | DOAJ |
| description | BackgroundHepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Increasing evidence revealed that long noncoding RNAs (lncRNAs) were frequently involved in various malignancies. Here, we explored the clinical significances, roles, and mechanisms of lncRNA ADORA2A antisense RNA 1 (ADORA2A-AS1) in HCC.MethodsThe clinical significances of ADORA2A-AS1 in HCC were analyzed using RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) project. The expressions of ADORA2A-AS1, Fascin Actin-Bundling Protein 1 (FSCN1), Matrix Metallopeptidase 2 (MMP2), and Baculoviral IAP Repeat Containing 7 (BIRC7) in HCC tissues and cells were measured by qRT-PCR. Cell Counting Kit-8 (CCK-8), 5-ethynyl-2’-deoxyuridine (EdU), caspase-3 activity assay, transwell migration and invasion assays, and xenograft growth and metastasis experiments were performed to evaluate the roles of ADORA2A-AS1 in HCC. RNA pull-down, RNA immunoprecipitation, qRT-PCR, Western blot, and RNA stability assay were performed to elucidate the mechanisms of ADORA2A-AS1 in HCC.ResultsADORA2A-AS1 was identified as an HCC-related lncRNA, whose low expression was correlated with advanced stage and poor outcome in HCC. Gain- and loss-of functional experiments demonstrated that ADORA2A-AS1 inhibited HCC cell proliferation, induced cell apoptosis, repressed cell migration and invasion, and repressed xenograft growth and metastasis in vivo. Mechanistically, ADORA2A-AS1 competitively bound HuR (Hu Antigen R), repressed the binding of HuR to FSCN1 transcript, decreased FSCN1 transcript stability, and downregulated FSCN1 expression. The expression of FSCN1 was negatively correlated with ADORA2A-AS1 in HCC tissues. Through downregulating FSCN1, ADORA2A-AS1 repressed AKT pathway activation. Functional rescue assays showed that blocking of FSCN1/AKT axis abrogated the roles of ADORA2A-AS1 in HCC.ConclusionLow-expression ADORA2A-AS1 is correlated with poor survival of HCC patients. ADORA2A-AS1 exerts tumor-suppressive roles in HCC via binding HuR and repressing FSCN1/AKT axis. |
| first_indexed | 2024-12-19T17:33:41Z |
| format | Article |
| id | doaj.art-9d147d1e00884d81949505d4108e4e97 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T17:33:41Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9d147d1e00884d81949505d4108e4e972022-12-21T20:12:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.754835754835ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT AxisJian Pu0Ya Zhang1Anmin Wang2Zebang Qin3Chenyi Zhuo4Wenchuan Li5Zuoming Xu6Qianli Tang7Jianchu Wang8Huamei Wei9Department of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaGraduate College of Youjiang Medical University for Nationalities, Baise, ChinaGraduate College of Youjiang Medical University for Nationalities, Baise, ChinaGraduate College of Youjiang Medical University for Nationalities, Baise, ChinaDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaDepartment of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, ChinaBackgroundHepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Increasing evidence revealed that long noncoding RNAs (lncRNAs) were frequently involved in various malignancies. Here, we explored the clinical significances, roles, and mechanisms of lncRNA ADORA2A antisense RNA 1 (ADORA2A-AS1) in HCC.MethodsThe clinical significances of ADORA2A-AS1 in HCC were analyzed using RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) project. The expressions of ADORA2A-AS1, Fascin Actin-Bundling Protein 1 (FSCN1), Matrix Metallopeptidase 2 (MMP2), and Baculoviral IAP Repeat Containing 7 (BIRC7) in HCC tissues and cells were measured by qRT-PCR. Cell Counting Kit-8 (CCK-8), 5-ethynyl-2’-deoxyuridine (EdU), caspase-3 activity assay, transwell migration and invasion assays, and xenograft growth and metastasis experiments were performed to evaluate the roles of ADORA2A-AS1 in HCC. RNA pull-down, RNA immunoprecipitation, qRT-PCR, Western blot, and RNA stability assay were performed to elucidate the mechanisms of ADORA2A-AS1 in HCC.ResultsADORA2A-AS1 was identified as an HCC-related lncRNA, whose low expression was correlated with advanced stage and poor outcome in HCC. Gain- and loss-of functional experiments demonstrated that ADORA2A-AS1 inhibited HCC cell proliferation, induced cell apoptosis, repressed cell migration and invasion, and repressed xenograft growth and metastasis in vivo. Mechanistically, ADORA2A-AS1 competitively bound HuR (Hu Antigen R), repressed the binding of HuR to FSCN1 transcript, decreased FSCN1 transcript stability, and downregulated FSCN1 expression. The expression of FSCN1 was negatively correlated with ADORA2A-AS1 in HCC tissues. Through downregulating FSCN1, ADORA2A-AS1 repressed AKT pathway activation. Functional rescue assays showed that blocking of FSCN1/AKT axis abrogated the roles of ADORA2A-AS1 in HCC.ConclusionLow-expression ADORA2A-AS1 is correlated with poor survival of HCC patients. ADORA2A-AS1 exerts tumor-suppressive roles in HCC via binding HuR and repressing FSCN1/AKT axis.https://www.frontiersin.org/articles/10.3389/fonc.2021.754835/fullhepatocellular carcinomalong noncoding RNAprogressionHuRFascinAKT pathway |
| spellingShingle | Jian Pu Ya Zhang Anmin Wang Zebang Qin Chenyi Zhuo Wenchuan Li Zuoming Xu Qianli Tang Jianchu Wang Huamei Wei ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis Frontiers in Oncology hepatocellular carcinoma long noncoding RNA progression HuR Fascin AKT pathway |
| title | ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis |
| title_full | ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis |
| title_fullStr | ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis |
| title_full_unstemmed | ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis |
| title_short | ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis |
| title_sort | adora2a as1 restricts hepatocellular carcinoma progression via binding hur and repressing fscn1 akt axis |
| topic | hepatocellular carcinoma long noncoding RNA progression HuR Fascin AKT pathway |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.754835/full |
| work_keys_str_mv | AT jianpu adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT yazhang adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT anminwang adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT zebangqin adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT chenyizhuo adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT wenchuanli adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT zuomingxu adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT qianlitang adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT jianchuwang adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis AT huameiwei adora2aas1restrictshepatocellularcarcinomaprogressionviabindinghurandrepressingfscn1aktaxis |